Protagonist Therapeutics (PTGX) News Today $51.05 -1.48 (-2.82%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$51.08 +0.03 (+0.06%) As of 03/25/2025 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Advantage Alpha Capital Partners LPAdvantage Alpha Capital Partners LP trimmed its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 49.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,742 shares of the company's stockMarch 25 at 5:05 AM | marketbeat.comSummit Global Investments Purchases Shares of 23,557 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Summit Global Investments acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 23,557 shares of the company's stock, valued at approximately $909,000March 24 at 4:42 AM | marketbeat.comRaymond James Financial Inc. Acquires Shares of 303,313 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Raymond James Financial Inc. acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 303,313 shares of the company's stock,March 21, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Director Sells $217,000.00 in StockProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) Director William D. Waddill sold 4,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the transaction, the director now directly owns 13,130 shares of the company's stock, valued at approximately $712,302.50. This trade represents a 23.35 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 20, 2025 | marketbeat.comAlphaQuest LLC Lowers Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)AlphaQuest LLC trimmed its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 90.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,177 shares of the company's stock after selling 21,770 sMarch 20, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 578,409 shares of the compMarch 19, 2025 | marketbeat.comAnalysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?March 18, 2025 | msn.comProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 3.7% on Insider SellingProtagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 3.7% After Insider SellingMarch 18, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by US Bancorp DEUS Bancorp DE decreased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 72.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,130 shares of the company's stock afMarch 18, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Down 3.7% Following Insider SellingMarch 18, 2025 | americanbankingnews.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Skandinaviska Enskilda Banken AB publSkandinaviska Enskilda Banken AB publ increased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 35.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 310,650 shares of the companMarch 16, 2025 | marketbeat.comErste Asset Management GmbH Invests $526,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Erste Asset Management GmbH bought a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 13,500 shares of the company's stock, valued at approximatMarch 16, 2025 | marketbeat.comGreat Lakes Advisors LLC Reduces Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Great Lakes Advisors LLC reduced its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 11.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,947 shares of the company's stock after selling 7,678March 16, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali Sells 24,903 SharesProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CFO Asif Ali sold 24,903 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $58.73, for a total value of $1,462,553.19. Following the completion of the transaction, the chief financial officer now directly owns 62,821 shares in the company, valued at $3,689,477.33. This trade represents a 28.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.March 15, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 30,514 SharesProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the sale, the insider now directly owns 83,892 shares of the company's stock, valued at $4,676,140.08. This trade represents a 26.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.March 15, 2025 | marketbeat.comIs Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?March 15, 2025 | insidermonkey.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells $1,462,553.19 in StockMarch 15, 2025 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc.Victory Capital Management Inc. raised its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 84.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 240,817 shares of the company's stock after purchasing an additional 110,020 sharesMarch 14, 2025 | marketbeat.comJ.P. Morgan Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)March 13, 2025 | markets.businessinsider.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon CorpBank of New York Mellon Corp lifted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 9.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 390,788 shares of the coMarch 13, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Reaches New 12-Month High After Analyst UpgradeProtagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High Following Analyst UpgradeMarch 12, 2025 | marketbeat.comTruist Financial Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $76.00Truist Financial upped their price target on Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a research report on Tuesday.March 12, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Given New $72.00 Price Target at BMO Capital MarketsBMO Capital Markets upped their price objective on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a research note on Tuesday.March 12, 2025 | marketbeat.comProtagonist Therapeutics price target raised to $72 from $62 at BMO CapitalMarch 11, 2025 | markets.businessinsider.comProtagonist Therapeutics: Much More Than Rusfertide In Place To Carry ItMarch 11, 2025 | seekingalpha.comProtagonist Therapeutics price target raised to $76 from $60 at TruistMarch 11, 2025 | markets.businessinsider.comProtagonist Therapeutics price target raised to $70 from $58 at WedbushMarch 11, 2025 | markets.businessinsider.comWhy Protagonist Therapeutics, Inc. (PTGX) Went Up on MondayMarch 11, 2025 | msn.comPTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis StudyMarch 11, 2025 | msn.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - Here's What HappenedProtagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - Here's What HappenedMarch 11, 2025 | marketbeat.comProtagonist Therapeutics price target raised to $80 from $54 at H.C. WainwrightMarch 11, 2025 | markets.businessinsider.comProtagonist Therapeutics Shares Rise After Positive Trial Data for IcotronkinraMarch 10, 2025 | marketwatch.comProtagonist reports top line results from Phase 2b study of icotrokinraMarch 10, 2025 | markets.businessinsider.comProtagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks OutMarch 10, 2025 | investors.comWhy Is Protagonist Therapeutics Stock Trading Higher On Monday?March 10, 2025 | benzinga.comProtagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $54.00 price target on shares of Protagonist Therapeutics in a report on Monday.March 10, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) have been given a consensus recommendation of "Buy" by the nine research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating, seven have given a buy ratMarch 6, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $57.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. raised their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Tuesday.March 4, 2025 | marketbeat.comNews Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under ThreatMarch 4, 2025 | finance.yahoo.comProtagonist Therapeutics price target raised to $73 from $67 at BTIGMarch 4, 2025 | markets.businessinsider.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - Here's WhyProtagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - Time to Buy?March 3, 2025 | marketbeat.comProtagonist Therapeutics' (PTGX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $54.00 target price on shares of Protagonist Therapeutics in a research note on Monday.March 3, 2025 | marketbeat.comProtagonist and Takeda's late stage trial for blood cancer treatment met main goalMarch 3, 2025 | msn.comProtagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia VeraMarch 3, 2025 | businesswire.comJPMorgan maintains Overweight on Protagonist Therapeutics stockMarch 2, 2025 | uk.investing.comLos Angeles Capital Management LLC Buys 8,920 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Los Angeles Capital Management LLC grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 39.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,366 shares of the company's stockMarch 2, 2025 | marketbeat.comHandelsbanken Fonder AB Takes $679,000 Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Handelsbanken Fonder AB bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 17,600 shares of the comMarch 2, 2025 | marketbeat.comPrincipal Financial Group Inc. Boosts Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Principal Financial Group Inc. boosted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 5.3% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 337,809 shares of the company's stock after buying an additional 16,977 shares durinFebruary 27, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for PTGX EarningsProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - HC Wainwright upped their Q1 2025 earnings estimates for Protagonist Therapeutics in a research report issued to clients and investors on Monday, February 24th. HC Wainwright analyst D. Tsao now expects that the company will post earninFebruary 26, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Reduces Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Allspring Global Investments Holdings LLC reduced its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 94.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,975 shares of the company's stock aftFebruary 26, 2025 | marketbeat.com Remove Ads Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Media Mentions By Week PTGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼1.020.79▲Average Medical News Sentiment PTGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼75▲PTGX Articles Average Week Remove Ads Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Dr. Reddy's Laboratories News Viatris News Ascendis Pharma A/S News Vaxcyte News Qiagen News Roivant Sciences News Sarepta Therapeutics News Revolution Medicines News BridgeBio Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTGX Stock Free PTGX Stock Alerts